| 93.49 1.05 (1.14%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 115.04 | 1-year : | 120.14 |
| Resists | First : | 98.5 | Second : | 102.86 |
| Pivot price | 98.31  |
|||
| Supports | First : | 91.44 | Second : | 76.08 |
| MAs | MA(5) : | 94.56 |
MA(20) : | 98.61 |
| MA(100) : | 90.62 |
MA(250) : | 92.17 |
|
| MACD | MACD : | -0.5 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 17 |
D(3) : | 19.1 |
| RSI | RSI(14): 40  |
|||
| 52-week | High : | 106.02 | Low : | 78.91 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ZBH ] has closed above bottom band by 9.0%. Bollinger Bands are 25.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 93.72 - 94.38 | 94.38 - 94.89 |
| Low: | 90.5 - 91.2 | 91.2 - 91.75 |
| Close: | 92.57 - 93.66 | 93.66 - 94.51 |
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
Sun, 13 Sep 2026
Zimmer Biomet Holdings (ZBH) Could Be 13% Below Fair Value After Leadership Reshuffle - simplywall.st
Sat, 12 Sep 2026
Engineers Gate Manager LP Makes New $6.16 Million Investment in Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Fri, 11 Sep 2026
Kevin R. Thornal plans $529K Zimmer Biomet (NYSE: ZBH) stock sale - stocktitan.net
Fri, 11 Sep 2026
Zimmer Biomet Holdings, Inc. $ZBH Shares Bought by Amundi - MarketBeat
Wed, 09 Sep 2026
Zimmer Biomet (NYSE: ZBH) officer sells 3,000 shares for about $295K - stocktitan.net
Tue, 08 Sep 2026
Is Zimmer Biomet Holdings Inc (ZBH) a Bargain After 3.9% Drop? G - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 191 (M) |
| Shares Float | 190 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 111.4 (%) |
| Shares Short | 8,800 (K) |
| Shares Short P.Month | 12,050 (K) |
| EPS | 4.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 66.23 |
| Profit Margin | 9.4 % |
| Operating Margin | 17.9 % |
| Return on Assets (ttm) | 3.9 % |
| Return on Equity (ttm) | 6.4 % |
| Qtrly Rev. Growth | 4.8 % |
| Gross Profit (p.s.) | 31.19 |
| Sales Per Share | 44.61 |
| EBITDA (p.s.) | 13.42 |
| Qtrly Earnings Growth | 33.7 % |
| Operating Cash Flow | 1,740 (M) |
| Levered Free Cash Flow | 1,090 (M) |
| PE Ratio | 22.69 |
| PEG Ratio | 0.6 |
| Price to Book value | 1.41 |
| Price to Sales | 2.09 |
| Price to Cash Flow | 10.24 |
| Dividend | 0.23 |
| Forward Dividend | 0 |
| Dividend Yield | 0.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|